Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  AIDS (London)

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002030-199910010-00029PMID 10513665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus.

  1998cited by this paper
• Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus.

  1998cited by this paper
• An audit of place of death of cancer patients in a semi-rural Scottish practice

  1998cited by this paper
• HIV-protease inhibitors.

  1998cited by this paper
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

  1998cited by this paper
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

  1998cited by this paper
• Protease inhibitor-associated hyperglycaemia.

  1997cited by this paper
• New-onset diabetes mellitus associated with use of protease inhibitor.

  1997cited by this paper
• Effects of aerosolized pentamidine on glucose homeostasis, and insulin secretion in HIV‐positive patients: a controlled study

  1995cited by this paper
• Transient insulin-dependent diabetes mellitus in an HIV-infected patient receiving didanosine.

  1994cited by this paper
• The Effects of Biosynthetic Human Proinsulin on Carbohydrate Metabolism

  1984cited by this paper

• COVID-19: Diabetes Perspective—Pathophysiology and Management

  2023cites this paper
• A Comprehensive Review of Anti-Diabetic Drugs in COVID-19 Patients Co-morbidities with Diabetes

  2022cites this paper
• Diabetes mellitus in combination with COVID-19: modern views on therapy

  2021cites this paper
• Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy.

  2021cites this paper
• COVID-19 and diabetes mellitus: from pathophysiology to clinical management

  2020cites this paper
• Chapter 10 Diabetic Ketoacidosis

  2019cites this paper
• Endocrine and Metabolic Emergencies in HIV and AIDS

  2014cites this paper
• Diagnosis and management of hyperglycemic emergencies

  2011cites this paper
• Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.

  2009cites this paper
• Pharmacologic Factors Affecting Glycemic Control

  2008cites this paper
• Diabetic ketoacidosis.

  2005cites this paper
• Protease Inhibitor-Induced Diabetic Complications

  2005cites this paper
• ‘Disappearing diabetes’—resolution of apparent Type 1 diabetes in a patient with AIDS and cytomegalovirus (CMV) infection

  2005cites this paper
• Insulin Resistance Complicating Pregnancy in a Human Immunodeficiency Virus–Infected Patient Treated With Protease Inhibitors and Corticosteroids

  2003cites this paper
• Safety aspects of HIV-protease inhibitors

  2002cites this paper
• Metformin in an HIV-Infected Patient with Protease Inhibitor—Induced Diabetic Ketoacidosis

  2001cites this paper